Current studies on drugs to combat COVID-19.
Vol. 2 No. 11 (2020), Editorial
Vol. 2 No. 11 (2020)

Current studies on drugs to combat COVID-19.

Editorial
https://doi.org/10.36557/2674-8169.2020v2n11p01-09
Published 2020-10-29
Eber Coelho Paraguassu
Specialized Dentistry Group (GOE): Macapá, Amapá, BR
Anneli Mercedes Celis de Cárdenas
Federal University of Amapá
PDF (Português (Brasil))

Keywords

Covid-19, Medicines, Pharmacology, Therapeutics, Treatment.

How to Cite

Coelho Paraguassu, E. ., & Celis de Cárdenas , A. M. . (2020). Current studies on drugs to combat COVID-19. Brazilian Journal of Implantology and Health Sciences, 2(11), 01–09. https://doi.org/10.36557/2674-8169.2020v2n11p01-09
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

A large-scale screening campaign yielded dozens of crystalline structures of small fragments of molecules that bind to the main SARS-CoV-2 protease. The global research community is encouraged to pursue them as starting points for drug discovery for COVID-19.

https://doi.org/10.36557/2674-8169.2020v2n11p01-09
PDF (Português (Brasil))

References

Douangamath, A. et al. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nat. Commun. https://doi.org/10.1038/s41467-020-18709-w (2020).

Zhang, L. et al. Alpha-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment. J. Med. Chem. 63, 4562–4578 (2020).

Jin, Z. et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 582, 289–293 (2020).

Dai, W. et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368, 1331–1335 (2020).

Erlanson, D. A., Fesik, S. W., Hubbard, R. E., Jahnke, W. & Jhoti, H. Twenty years on: the impact of fragments on drug discovery. Nat. Rev. Drug Discov. 15, 605–619 (2016).

Resnick, E. et al. Rapid covalent-probe discovery by electrophile-fragment screening. J. Am. Chem. Soc. 141, 8951–8968 (2019).

Abdeldayem, A., Raouf, Y. S., Constantinescu, S. N., Moriggl, R. & Gunning, P. T. Advances in covalent kinase inhibitors. Chem. Soc. Rev. 49, 2617–2687 (2020).

Mons, E. et al. The alkyne moiety as a latent electrophile in irreversible covalent small molecule inhibitors of cathepsin K. J. Am. Chem. Soc. 141, 3507–3514 (2019).

Di Lello, P. et al. Discovery of small-molecule inhibitors of ubiquitin specific protease 7 (USP7) using integrated NMR and in silico techniques. J. Med. Chem. 60, 10056–10070 (2017).

Gavory, G. et al. Discovery and characterization of highly potent and selective allosteric USP7 inhibitors. Nat. Chem. Biol. 14, 118–125 (2018).

Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677–681 (2005).

Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041–3046 (2008).

Sreeramulu, S. et al. NMR quality control of fragment libraries for screening. J. Biomol. NMR https://doi.org/10.1007/s10858-020-00327-9 (2020).

Irie, T. & Sawa, M. 7-azaindole: a versatile scaffold for developing kinase inhibitors. Chem. Pharm. Bull. (Tokyo) 66, 29–36 (2018).

Erlanson, D. A., de Esch, I. J. P., Jahnke, W., Johnson, C. N. & Mortenson, P. N. Fragment-to-lead medicinal chemistry publications in 2018. J. Med. Chem. 63, 4430–4444 (2020).

Tron, A. E. et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat. Commun. 9, 5341 (2018).

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2020 Eber Coelho Paraguassu, Anneli Mercedes Celis de Cárdenas